14. 5. 2014
Krka presented its first quarter 2014 operating results
2 min. read
The Management Board of Krka presented to the public the performance results of the Krka Group and the Krka Company for the first three months of the year.
Krka Group sales amounted to EUR 298.0 million in the first three months of 2014, up EUR 3.6 million, or 1%, compared to the same period last year. Sales in markets outside Slovenia amounted to EUR 278.7 million, which is 94% of the Group’s total sales and an increase by EUR 5.4 million, or 2%, compared to the same period last year.
Krka Company sales totalled EUR 288.6 million, up EUR 4.1 million, or 1%, compared to the same period last year.
The Krka Group sold EUR 248.3 million worth of prescription pharmaceuticals in the reported period, 2% more than in the same period last year. Prescription pharmaceuticals represent 83.3% of Krka Group sales.
In the three months of 2014 the Krka Group obtained first marketing authorisations for five new products in 12 dosage forms and strengths, and they obtained a total of 119 new marketing authorisations for 50 products in different markets.
In the first quarter of 2014 the Krka Group allocated EUR 46.2 million to investments, of which the controlling company invested EUR 42.1 million and subsidiaries EUR 4.1 million. Investments are primarily increasing and modernising their production capacities, and research and development capacities. Over 20 investment projects are currently ongoing in the Krka Group.